Toll‑like receptor 4 monoclonal antibody attenuates lipopolysaccharide‑induced acute lung injury in mice

He,Zhijie; Chen,Xiaotong; Wang,Shouping; Zou,Zijun

doi:10.3892/etm.2014.1805

Toll‑like receptor 4 monoclonal antibody attenuates lipopolysaccharide‑induced acute lung injury in mice

Authors:
- Zhijie He
- Xiaotong Chen
- Shouping Wang
- Zijun Zou
View Affiliations

Affiliations: Department of Critical Care Medicine, Sun Yat‑sen Memorial Hospital, University of Sun Yat‑sen, Guangzhou, Guangdong 510120, P.R. China, Department of Anesthesiology, Sun Yat‑sen Memorial Hospital, University of Sun Yat‑sen, Guangzhou, Guangdong 510120, P.R. China
Published online on: June 24, 2014 https://doi.org/10.3892/etm.2014.1805
Pages: 871-876

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Toll‑like receptor 4 (TLR4) has an important role in the recognition of lipopolysaccharide (LPS) and in the activation of the inflammatory cascade. In the present study, the effect of TLR4 monoclonal antibody (mAb) on LPS‑induced acute lung injury (ALI) was investigated in mice. A total of 45 male BALB/c mice were randomly divided into three groups, namely, the control (group C), sepsis (group S) and pretreatment groups (group P). Mice in group P were intraperitoneally treated with TLR4 mAb 1 h prior to the intraperitoneal administration of LPS. Following treatment with LPS for increasing times periods in groups S and P, the mRNA expression level of TLR4 in the lung tissue and the expression of inflammatory factors in the serum were analyzed by quantitative polymerase chain reaction and enzyme‑linked immunosorbent assays, respectively. The degree of pulmonary edema, expressed as (wet weight ‑ dry weight)/wet weight, as well as the lung injury scores, observed using a light microscope, were also analyzed. The results demonstrated that intraperitoneal administration of LPS in mice increased the mRNA expression levels of TLR4, the secretion of inflammatory factors in the serum, the degree of pulmonary edema and the lung injury score in a time‑dependent manner. However, pretreatment with TLR4 mAb effectively attenuated the increased mRNA expression of TLR4 and the overproduction of inflammatory factors to correct the pulmonary edema and the elevated lung injury score induced by LPS. Therefore, TLR4 plays a critical role in LPS‑induced ALI, and the TLR4 mAb decreases the secretion of inflammatory factors and attenuates the degree of pulmonary edema, thereby protecting the lungs from LPS‑induced ALI.

View Figures

View References

1	Cohen J: The immunopathogenesis of sepsis. Nature. 420:885–891. 2002. View Article : Google Scholar : PubMed/NCBI
2	Ware LB and Matthay MA: The acute respiratory distress syndrome. N Engl J Med. 342:1334–1349. 2000. View Article : Google Scholar : PubMed/NCBI
3	Densmore JC, Signorino PR, Ou J, et al: Endothelium-derived microparticles induce endothelial dysfunction and acute lung injury. Shock. 26:464–471. 2006. View Article : Google Scholar : PubMed/NCBI
4	Cribbs SK, Matthay MA and Martin GS: Stem cells in sepsis and acute lung injury. Crit Care Med. 38:2379–2385. 2010. View Article : Google Scholar : PubMed/NCBI
5	Imai Y, Kuba K, Neely GG, et al: Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell. 133:235–249. 2008. View Article : Google Scholar : PubMed/NCBI
6	Xu Y, Jagannath C, Liu XD, Sharafkhaneh A, Kolodziejska KE and Eissa NT: Toll-like receptor 4 is a sensor for autophagy associated with innate immunity. Immunity. 27:135–144. 2007. View Article : Google Scholar : PubMed/NCBI
7	Shirey KA, Lai W, Scott AJ, et al: The TLR4 antagonist Eritoran protects mice from lethal influenza infection. Nature. 497:498–502. 2013. View Article : Google Scholar : PubMed/NCBI
8	Tong Q, Zheng L, Kang Q, Dodd-O J, Langer J, Li B, Wang D and Li D: Upregulation of hypoxia-induced mitogenic factor in bacterial lipopolysaccharide-induced acute lung injury. FEBS Lett. 580:2207–2215. 2006. View Article : Google Scholar : PubMed/NCBI
9	Szarka RJ, Wang N, Gordon L, Nation PN and Smith RH: A murine model of pulmonary damage induced by lipopolysaccharide via intranasal instillation. J Immunol Methods. 202:49–57. 1997. View Article : Google Scholar : PubMed/NCBI
10	Mrozek JD, Smith KM, Bing DR, Meyers PA, Simonton SC, Connett JE and Mammel MC: Exogenous surfactant and partial liquid ventilation: physiologic and pathologic effects. Am J Respir Crit Care Med. 156:1058–1065. 1997. View Article : Google Scholar : PubMed/NCBI
11	Rotta AT and Steinhorn DM: Partial liquid ventilation reduces pulmonary neutrophil accumulation in an experimental model of systemic endotoxemia and acute lung injury. Crit Care Med. 26:1707–1715. 1998. View Article : Google Scholar : PubMed/NCBI
12	Nahum A, Hoyt J, Schmitz L, Moody J, Shapiro R and Marini JJ: Effect of mechanical ventilation strategy on dissemination of intratracheally instilled Escherichia coli in dogs. Crit Care Med. 25:1733–1743. 1997. View Article : Google Scholar : PubMed/NCBI
13	Rock FL, Hardiman G, Timans JC, Kastelein RA and Bazan JF: A family of human receptors structurally related to Drosophila Toll. Proc Natl Acad Sci USA. 95:588–593. 1998. View Article : Google Scholar : PubMed/NCBI
14	Akira S, Uematsu S and Takeuchi O: Pathogen recognition and innate immunity. Cell. 124:783–801. 2006. View Article : Google Scholar
15	Kumar H, Kawai T and Akira S: Pathogen recognition by the innate immune system. Int Rev Immunol. 30:16–34. 2011. View Article : Google Scholar
16	Huang S, Miao R, Zhou Z, et al: MCPIP1 negatively regulates Toll-like receptor 4 signaling and protects mice from LPS-induced septic shock. Cell Signal. 25:1228–1234. 2013. View Article : Google Scholar : PubMed/NCBI
17	Jenkins KA and Mansell A: TIR-containing adaptors in Toll-like receptor signalling. Cytokine. 49:237–244. 2010. View Article : Google Scholar : PubMed/NCBI
18	López-Bojórquez LN, Dehesa AZ and Reyes-Terán G: Molecular mechanisms involved in the pathogenesis of septic shock. Arch Med Res. 35:465–479. 2004.
19	Abraham E, Anzueto A, Gutierrez G, et al: Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group Lancet. 351:929–933. 1998. View Article : Google Scholar : PubMed/NCBI
20	Fisher CJ Jr, Dhainaut JF, Opal SM, et al: Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA. 271:1836–1843. 1994. View Article : Google Scholar
21	O‘Neill LA and Bowie AG: The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat Rev Immunol. 7:353–364. 2007.
22	Li Y, Zhong S and Yao R: Influence of LPS and Toll-like receptor 4 antagonist on progesterone receptor, interleukin-1β, and cyclooxygenase-2 in decidual cells. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 38:162–168. 2013.(In Chinese).
23	Tsukamoto H, Fukudome K, Takao S, Tsuneyoshi N, Ihara H, Ikeda Y and Kimoto M: Multiple potential regulatory sites of TLR4 activation induced by LPS as revealed by novel inhibitory human TLR4 mAbs. Int Immunol. 24:495–506. 2012. View Article : Google Scholar : PubMed/NCBI
24	Norman JG, Fink GW and Franz MG: Acute pancreatitis induces intrapancreatic tumor necrosis factor gene expression. Arch Surg. 130:966–970. 1995. View Article : Google Scholar : PubMed/NCBI
25	Putensen C and Wrigge H: Ventilator-associated systemic inflammation in acute lung injury. Intensive Care Med. 26:1411–1413. 2000. View Article : Google Scholar : PubMed/NCBI
26	Bhatia M, Brady M, Shokuhi S, Christmas S, Neoptolemos JP and Slavin J: Inflammatory mediators in acute pancreatitis. J Pathol. 190:117–125. 2000. View Article : Google Scholar
27	Bhatia M, Neoptolemos JP and Slavin J: Inflammatory mediators as therapeutic targets in acute pancreatitis. Curr Opin Investig Drugs. 2:496–501. 2001.PubMed/NCBI
28	Bhatia M: Novel therapeutic targets for acute pancreatitis and associated multiple organ dysfunction syndrome. Curr Drug Targets Inflamm Allergy. 1:343–351. 2002. View Article : Google Scholar : PubMed/NCBI
29	Geiger T, Andus T, Klapproth J, Hirano T, Kishimoto T and Heinrich PC: Induction of rat acute-phase proteins by interleukin 6 in vivo. Eur J Immunol. 18:717–721. 1988. View Article : Google Scholar : PubMed/NCBI
30	Castell JV, Gómez-Lechón MJ, David M, et al: Interleukin-6 is the major regulator of acute phase protein synthesis in adult human hepatocytes. FEBS Lett. 242:237–239. 1989. View Article : Google Scholar : PubMed/NCBI
31	Remick DG, Bolgos GR, Siddiqui J, Shin J and Nemzek JA: Six at six: interleukin-6 measured 6 h after the initiation of sepsis predicts mortality over 3 days. Shock. 17:463–467. 2002. View Article : Google Scholar : PubMed/NCBI
32	Szatmary Z: Molecular biology of Toll-like receptors. Gen Physiol Biophys. 31:357–366. 2012. View Article : Google Scholar : PubMed/NCBI
33	Liew FY, Xu D, Brint EK and O‘Neill LA: Negative regulation of Toll-like receptor-mediated immune responses. Nat Rev Immunol. 5:446–458. 2005. View Article : Google Scholar : PubMed/NCBI